MX2012012615A - Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs). - Google Patents
Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs).Info
- Publication number
- MX2012012615A MX2012012615A MX2012012615A MX2012012615A MX2012012615A MX 2012012615 A MX2012012615 A MX 2012012615A MX 2012012615 A MX2012012615 A MX 2012012615A MX 2012012615 A MX2012012615 A MX 2012012615A MX 2012012615 A MX2012012615 A MX 2012012615A
- Authority
- MX
- Mexico
- Prior art keywords
- fxs
- fragile
- syndrome
- treatment
- markers useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
La invención se refiere al uso de biomarcadores para determinar la posibilidad de respuesta de un individuo con síndrome X frágil (FXS) al tratamiento con un antagonista del receptor de glutamato metabotrópico 5 (mGluR5).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33029910P | 2010-04-30 | 2010-04-30 | |
US37919710P | 2010-09-01 | 2010-09-01 | |
PCT/US2011/034244 WO2011137206A1 (en) | 2010-04-30 | 2011-04-28 | Predictive markers useful in the treatment of fragile x syndrome (fxs) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012012615A true MX2012012615A (es) | 2012-12-17 |
Family
ID=44121075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012012615A MX2012012615A (es) | 2010-04-30 | 2011-04-28 | Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs). |
Country Status (21)
Country | Link |
---|---|
US (1) | US20130052644A1 (es) |
EP (1) | EP2563934A1 (es) |
JP (1) | JP2013524840A (es) |
KR (1) | KR20130100906A (es) |
CN (1) | CN102869791A (es) |
AU (1) | AU2011245372A1 (es) |
BR (1) | BR112012027816A2 (es) |
CA (1) | CA2797854A1 (es) |
CL (1) | CL2012003027A1 (es) |
EC (1) | ECSP12012317A (es) |
GT (1) | GT201200293A (es) |
IL (1) | IL222534A0 (es) |
MA (1) | MA34263B1 (es) |
MX (1) | MX2012012615A (es) |
PE (1) | PE20130213A1 (es) |
RU (1) | RU2012151273A (es) |
SG (1) | SG184458A1 (es) |
TN (1) | TN2012000485A1 (es) |
TW (1) | TW201142293A (es) |
WO (1) | WO2011137206A1 (es) |
ZA (1) | ZA201207481B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
NZ608972A (en) | 2010-10-01 | 2015-09-25 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
WO2012084873A1 (en) * | 2010-12-20 | 2012-06-28 | Novartis Ag | 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
CN110201187A (zh) | 2011-12-16 | 2019-09-06 | 现代泰克斯公司 | 经修饰的核苷、核苷酸和核酸组合物 |
WO2013131981A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs) |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014152600A2 (en) * | 2013-03-15 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CA2926645C (en) | 2013-10-14 | 2022-10-25 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate erk 1/2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
CN103981253A (zh) * | 2014-03-27 | 2014-08-13 | 江苏佰龄全基因生物医学技术有限公司 | 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒 |
WO2022104098A1 (en) * | 2020-11-13 | 2022-05-19 | Children's Hospital Medical Center | Refined uses of gabaa receptor modulators in treatment of fragile x syndrome |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US6143504A (en) * | 1998-10-27 | 2000-11-07 | Arch Development Corporation | Methods and compositions for the diagnosis of fragile X syndrome |
GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
MXPA05001594A (es) | 2002-08-09 | 2005-09-20 | Astrazeneca Ab | 1,2,4" oxadiazoles como moduladores de receptor-5 metabotropico de glutamato. |
JP4453297B2 (ja) | 2003-05-27 | 2010-04-21 | トヨタ自動車株式会社 | 車両用遊星歯車式多段変速機 |
TW200801005A (en) | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Acetylenic piperazines as metabotropic glutamate receptor antagonists |
WO2007044780A2 (en) * | 2005-10-07 | 2007-04-19 | Emory University | Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies |
US7855053B2 (en) * | 2006-07-19 | 2010-12-21 | The Regents Of The University Of California | Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region |
KR20110056499A (ko) | 2008-08-04 | 2011-05-30 | 노파르티스 아게 | 폴리q 단백질에 대한 바이오어세이 |
US20100248239A1 (en) * | 2009-03-24 | 2010-09-30 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting fragile x mutations |
-
2011
- 2011-04-28 MA MA35412A patent/MA34263B1/fr unknown
- 2011-04-28 AU AU2011245372A patent/AU2011245372A1/en not_active Abandoned
- 2011-04-28 US US13/695,214 patent/US20130052644A1/en not_active Abandoned
- 2011-04-28 EP EP11719705A patent/EP2563934A1/en not_active Withdrawn
- 2011-04-28 RU RU2012151273/10A patent/RU2012151273A/ru not_active Application Discontinuation
- 2011-04-28 CA CA2797854A patent/CA2797854A1/en not_active Abandoned
- 2011-04-28 PE PE2012002106A patent/PE20130213A1/es not_active Application Discontinuation
- 2011-04-28 KR KR1020127031312A patent/KR20130100906A/ko not_active Application Discontinuation
- 2011-04-28 WO PCT/US2011/034244 patent/WO2011137206A1/en active Application Filing
- 2011-04-28 CN CN2011800219070A patent/CN102869791A/zh active Pending
- 2011-04-28 JP JP2013508235A patent/JP2013524840A/ja active Pending
- 2011-04-28 BR BR112012027816A patent/BR112012027816A2/pt not_active IP Right Cessation
- 2011-04-28 MX MX2012012615A patent/MX2012012615A/es not_active Application Discontinuation
- 2011-04-28 SG SG2012074035A patent/SG184458A1/en unknown
- 2011-04-29 TW TW100115217A patent/TW201142293A/zh unknown
-
2012
- 2012-10-05 TN TNP2012000485A patent/TN2012000485A1/en unknown
- 2012-10-05 ZA ZA2012/07481A patent/ZA201207481B/en unknown
- 2012-10-18 IL IL222534A patent/IL222534A0/en unknown
- 2012-10-29 CL CL2012003027A patent/CL2012003027A1/es unknown
- 2012-10-30 GT GT201200293A patent/GT201200293A/es unknown
- 2012-11-29 EC ECSP12012317 patent/ECSP12012317A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011245372A1 (en) | 2012-11-29 |
PE20130213A1 (es) | 2013-03-19 |
IL222534A0 (en) | 2012-12-31 |
GT201200293A (es) | 2014-06-09 |
KR20130100906A (ko) | 2013-09-12 |
EP2563934A1 (en) | 2013-03-06 |
MA34263B1 (fr) | 2013-05-02 |
US20130052644A1 (en) | 2013-02-28 |
SG184458A1 (en) | 2012-11-29 |
RU2012151273A (ru) | 2014-06-10 |
BR112012027816A2 (pt) | 2017-08-08 |
CA2797854A1 (en) | 2011-11-03 |
TW201142293A (en) | 2011-12-01 |
WO2011137206A1 (en) | 2011-11-03 |
CN102869791A (zh) | 2013-01-09 |
ZA201207481B (en) | 2013-06-26 |
JP2013524840A (ja) | 2013-06-20 |
CL2012003027A1 (es) | 2014-02-14 |
TN2012000485A1 (en) | 2014-04-01 |
ECSP12012317A (es) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2012000485A1 (en) | Predictive markers useful in the treatment of fragile x syndrome (fxs) | |
CY2020025I1 (el) | Αναστολεις βητα-λακταμασων | |
CY2019009I1 (el) | Αναστολεις πρωτεϊνικων κινασων | |
SMT201600135B (it) | Nuovi inibitori della s-nitrosoglutatione riduttasi | |
ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
HK1167655A1 (zh) | -末端激酶抑制劑 | |
MY170983A (en) | Biomarker assays for detecting or measuring inhibition of tor kinase activity | |
BRPI1013392A2 (pt) | inibidor do inibidor-1 do ativador do plasminogênio | |
BR112012000934A2 (pt) | cassetes e métodos de utilizacao destes | |
BRPI1011129A2 (pt) | métodos e compostos inibidores de janus cinase | |
FI20075600A0 (fi) | Komponentin eliniän määritys | |
ES2608829T8 (es) | Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida | |
BRPI1007815A2 (pt) | substratos porosos hidrofílicos | |
ITMI20120140A1 (it) | Procedimento per la determinazione della posizione di un apparecchio traslabile autonomamente o semovente | |
SMT201500264B (it) | Mutanti della frataxina | |
WO2012137180A3 (en) | Biomarkers of immunotherapy efficacy | |
BRPI0911480A2 (pt) | inibidores de proteínas serina-treonina quinase ikk-beta | |
FI20085102A (fi) | Probioottien uusi käyttö | |
IT1400309B1 (it) | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. | |
IT1400609B1 (it) | Associazione di inibitori della xantina ossidasi e metformina e loro uso. | |
FR2937125B1 (fr) | Determination de grandeurs mesurables geolocalisees. | |
TH125498B (th) | สารยับยั้งไพริโดไพริมิดิโนนของ P13Ka และ mTOR | |
TH0801005307A (th) | การใช้สารกระตุ้นพลาสมิโนเจน | |
TH0901005542B (th) | ตัวยับยั้งโปรตีนคิเนส | |
TH104263B (th) | สารยับยั้งของแอคติวิตี้ของโปรตีนไทโรซีนไคเนส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |